BioSpace News Archive

Praxis Precision Medicines , Inc. today announced that management will participate in the “Got My Mind Set On You – Advancing Novel Epilepsy Targets” panel at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

NeuroOne Medical Technologies Corporation today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc.

Zynex, Inc. announced the Denver Business Journal has ranked Zynex number 50 in a list Colorado-based public companies, according to 2021 revenue figures.

Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with specific Level 1® H-2 Pressure Chambers used with the Level 1 Fast Flow Fluid Warmers.

GLO Pharma, the parent company of breakthrough subtopical skincare brand Ourself, announces the promotion of Vimla Black-Gupta to CEO of Ourself.

Citing a “substantial unmet need,” a new paper from the Clinical Neurological Society of America offers unique insights from health care providers into the delusions, aggression and agitation that often accompany Alzheimer’s disease.

NEW ‘Transparency Talks’ With Pfizer and Global Pricing Innovations Help Pharmaceutical Companies Stay Compliant With Drug Pricing Model N, Inc., the leader in revenue optimization and compliance, announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) will reconvene to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS).

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC).

Kaia Health, the largest global digital therapeutics company on a mission to make high-quality, evidence-based therapies accessible to anyone, anytime, today announced results from the Rise-uP randomized controlled trial, which demonstrated that the use of digital multimodal therapy leads to a significant reduction in back pain.